Narcolepsy

Minerva Pneumologica

Volumn 48, Issue 4, 2009, Pages 345-375

  Zarowski, M ^a   Ali Dinar, T ^b   Kothare, S V ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cataplexy; Narcolepsy, diagnosis; Narcolepsy, epidemiology; Narcolepsy, therapy; Sleep

Indexed keywords

ANTIHISTAMINIC AGENT; ARMODAFINIL; ATOMOXETINE; CAFFEINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DEXAMPHETAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAZINDOL; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; NORADRENALIN UPTAKE INHIBITOR; OXYBATE SODIUM; PEMOLINE; PROTRIPTYLINE; PSYCHOSTIMULANT AGENT; REBOXETINE; RITANSERIN; SEDATIVE AGENT; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; VILOXAZINE;

AGGRESSION; ANAMNESIS; ANOREXIA; ANXIETY DISORDER; BEHAVIOR THERAPY; CATAPLEXY; CLINICAL FEATURE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DAYTIME SOMNOLENCE; DEPRESSION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG OVERDOSE; EARLY DIAGNOSIS; ENURESIS; ENVIRONMENTAL FACTOR; EPIDEMIOLOGICAL DATA; FAMILY HISTORY; FATIGUE; GASTROINTESTINAL SYMPTOM; GENETIC ASSOCIATION; GENETIC RISK; HALLUCINATION; HEART ARRHYTHMIA; HEART PALPITATION; HUMAN; HYPERHIDROSIS; HYPERSOMNIA; HYPERTENSION; HYPNAGOGIC HALLUCINATION; INFECTION; INSOMNIA; IRRITABILITY; LIBIDO DISORDER; LIFESTYLE MODIFICATION; LIVER TOXICITY; MENTAL DISEASE; MIGRAINE; MORNING DOSAGE; MUSCLE TWITCH; NARCOLEPSY; NAUSEA; NERVOUSNESS; NEUROLOGIC EXAMINATION; NIGHTMARE; ONSET AGE; ORTHOSTATIC HYPOTENSION; PAIN; PARASOMNIA; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; POLYSOMNOGRAPHY; PREVALENCE; PSYCHOSIS; QUALITY OF LIFE; RESTLESSNESS; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SLEEP; SLEEP APNEA SYNDROME; SLEEP DISORDER; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SUICIDE ATTEMPT; SWEATING; TREMOR; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 77949593938     PISSN: 00264954     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (331)

1. Gélineau J. De la narcolepsie. Gaz Hôp Civil Milit 1880;53:626-8, 635-7.
2. Daniels L. Narcolepsy. Medicine 1934;13:122.
3. Mignot E. A hundred years of narcolepsy research. Arch Ital Biol 2001;139:207-20.
4. Yoss RE, Daly DD. Criteria for the diagnosis of the narcoleptic syndrome. Proc Staff Meet Mayo Clin 1957;32:320-8.
5. Vogel G. Studies in psychophysiology of dreams. III. The dream of narcolepsy. Arch Gen Psychiatry 1960;3:421-8.
6. The international classification of sleep disorders diagnostic and coding manual 2nd ed. Westchester, IL: American Academy of Sleep Medicine; 2005.
7. Guilleminault C, Pelayo R. Narcolepsy in children: a practical guide to its diagnosis, treatment and follow-up. Paediatr Drugs 2000;2:1-9.
8. Nevsimalova S. Narcolepsy in childhood. Sleep Med Rev 2009;13:169-80.
9. Ohayon MM, Ferini-Strambi L, Plazzi G, Smirne S, Castronovo V. Frequency of narcolepsy symptoms and other sleep disorders in narcoleptic patients and their first-degree relatives. J Sleep Res 2005;14:437-45.
10. Ohayon MM, Priest RG, Zulley J, Smirne S, Paiva T. Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology 2002;58:1826-33.
11. Dement W, Zarcone W, Varner V, Hoddes E, Nassau S, Jacobs BL. The prevalence of narcolepsy. Sleep Res 1972;1.
12. Silber MH, Krahn LE, Olson EJ, Pankratz VS. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep 2002;25:197-202.
13. Longstreth WT Jr, Ton TG, Koepsell T, Gersuk VH, Hendrickson A, Velde S. Prevalence of narcolepsy in King County, Washington, USA. Sleep Med 2009;10:422-6.
14. Longstreth WT Jr, Koepsell TD, Ton TG, Hendrickson AF, van Belle G. The epidemiology of narcolepsy. Sleep 2007;30:13-26.
15. Franceschi M, Zamproni P, Crippa D, Smirne S. Excessive daytime sleepiness: a 1-year study in an unselected inpatient population. Sleep 1982;5:239-47.
16. Hublin C, Kaprio J, Partinen M, Koskenvuo M, Heikkila K, Koskimies S et al. The prevalence of narcolepsy: an epidemiological study of the Finnish Twin Cohort. Ann Neurol 1994;35:709-16.
17. Heier MS, Evsiukova T, Wilson J, Abdelnoor M, Hublin C, Ervik S. Prevalence of narcolepsy with cataplexy in Norway. Acta Neurol Scand 2009;120:276-80.
18. Honda K. Census of narcolepsy, cataplexy and sleep life among teenagers in Fujisawa City. Sleep Res 1979;8.
19. Tashiro T, Kanbayashi T, Iijima S, Hishikawa Y. An epidemiological study on prevalence of narcolepsy in Japanese. J Sleep Res 1992;1(Supp).
20. al Rajeh S, Bademosi O, Ismail H, Awada A, Dawodu A, al-Freihi H et al. A community survey of neurological disorders in Saudi Arabia: the Thugbah study. Neuroepidemiology 1993;12:164-78.
21. Wing YK, Chiu HF, Ho CK, Chen CN. Narcolepsy in Hong Kong Chinese a preliminary experience. Aust N Z J Med 1994;24:304-6.
22. Wing YK, Li RH, Lam CW, Ho CK, Fong SY, Leung T. The prevalence of narcolepsy among Chinese in Hong Kong. Ann Neurol 2002;51:578-84.
23. Shin YK, Yoon IY, Han EK, No YM, Hong MC, Yun YD et al. Prevalence of narcolepsy-cataplexy in Korean adolescents. Acta Neurol Scand 2008;117:273-8.
24. Oksenberg J, Amar A, Cohen N, Grosse-Wilde H, Cohen I, Sharon R et al. HLA-D "BG" in Israel. A Japanese related allele population and family study. Tissue Antigens 1983;21:271-80.
25. Lavie P, Peled R. Narcolepsy is a rare disease in Israel. Sleep 1987;10:608-9.
26. Wilner A, Steinman L, Lavie P, Peled R, Friedmann A, Brautbar C. Narcolepsy-cataplexy in Israeli Jews is associated exclusively with the HLA DR2 haplotype. A study at the serological and genomic level. Hum Immunol 1988;21:15-22.
27. Thorpy M. Current concepts in the etiology, diagnosis and treatment of narcolepsy. Sleep Med 2001;2:5-17.
28. Dauvilliers Y, Montplaisir J, Molinari N, Carlander B, Ondze B, Besset A et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 2001;57:2029-33.
29. Han F, Chen E, Wei H, Dong X, He Q, Ding D et al. Childhood narcolepsy in North China. Sleep 2001;24:321-4.
30. Ohayon MM, Ferini-Strambi L, Plazzi G, Smirne S, Castronovo V. How age influences the expression of narcolepsy. J Psychosom Res 2005;59:399-405.
31. Thorpy M. Therapeutic advances in narcolepsy. Sleep Med 2007;8:427-40.
32. Vendrame M, Havaligi N, Matadeen-Ali C, Adams R, Kothare SV. Narcolepsy in children: a single-center clinical experience. Pediatr Neurol 2008;38:314-20.
33. Nevsimalova S, Buskova J, Kemlink D, Sonka K, Skibova J. Does age at the onset of narcolepsy influence the course and severity of the disease? Sleep Med 2009;10:967-72.
34. Krabbe E, Magnussen G. Familial narcolepsy. Acta Psychiatr Neurol 1942;11:149-73.
35. Baraitser M, Parkes JD. Genetic study of narcoleptic syndrome. J Med Genet 1978;15:254-9.
36. Billiard M, Pasquie-Magnetto V, Heckman M, Carlander B, Besset A, Zachariev Z et al. Family studies in narcolepsy. Sleep 1994;17(8 Suppl):S54-9.
37. Hayduk R, Flodman P, Spence MA, Erman MK, Mitler MM. HLA haplotypes, polysomnography, and pedigrees in a case series of patients with narcolepsy. Sleep 1997;20:850-7.
38. Guilleminault C, Mignot E, Grumet FC. Familial patterns of narcolepsy. Lancet 1989;2:1376-9.
39. Nevsimalova S, Mignot E, Sonka K, Arrigoni JL. Familial aspects of narcolepsy-cataplexy in the Czech Republic. Sleep 1997;20:1021-6.
40. Maret S, Tafti M. Genetics of narcolepsy and other major sleep disorders. Swiss Med Wkly 2005;135:662-5.
41. Mignot E. Genetics of narcolepsy and other sleep disorders. Am J Hum Genet 1997;60:1289-302.
42. Honda M, Honda Y, Uchida S, Miyazaki S, Tokunaga K. Monozygotic twins incompletely concordant for narcolepsy. Biol Psychiatry 2001;49:943-7.
43. Partinen M, Hublin C, Kaprio J, Koskenvuo M, Guilleminault C. Twin studies in narcolepsy. Sleep 1994;17(8 Suppl):S13-6.
44. Pollmacher T, Schulz H, Geisler P, Kiss E, Albert ED, Schwarzfischer F. DR2-positive monozygotic twins discordant for narcolepsy. Sleep 1990;13:336-43.
45. Kales A, Cadieux RJ, Soldatos CR, Bixler EO, Schweitzer PK, Prey WT et al. Narcolepsy-cataplexy. I. Clinical and electrophysiologic characteristics. Arch Neurol 1982;39:164-8.
46. Neely S, Rosenberg R, Spire JP, Antel J, Arnason BG. HLA antigens in narcolepsy. Neurology 1987;37:1858-60.
47. Mignot E, Lin L, Rogers W, Honda Y, Qiu X, Lin X et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet 2001;68:686-99.
48. Rogers AE, Meehan J, Guilleminault C, Grumet FC, Mignot E. HLA DR15 (DR2) and DQB1*0602 typing studies in 188 narcoleptic patients with cataplexy. Neurology 1997;48:1550-6.
49. Scammell TE. The neurobiology, diagnosis, and treatment of narcolepsy. Ann Neurol 2003:53:154-66.
50. Baust W, Holzbach E, Zechlin O. Phasic changes in heart rate and respiration correlated with PGO-spike activity during REM sleep Pflugers Arch 1972;331:113-23.
51. Salin-Pascual R, Gerashchenko D, Greco M, Blanco-Centurion C, Shiromani PJ. Hypothalamic regulation of sleep. Neuropsychopharmacology 2001;25(5 Suppl):S21-7.
52. John J, Wu MF, Boehmer LN, Siegel JM. Cataplexy-active neurons in the hypothalamus: implications for the role of histamine in sleep and waking behavior. Neuron 2004;42:619-34.
53. Chase M, Morales F. Control of motoneurons during sleep. In: Kryger MH, Roth T, Dement W, editors. Principles and practice of sleep medicine. Philadelphi, PA: Elsevier Saunders; 2005. p. 154-68.
54. Siegel JM. REM sleep. In: Kryger MH, Roth T, Dement W, editors. Principles and practice of sleep medicine. Philadelphi, PA: Elsevier Saunders; 2005. p. 1552.
55. Taepavarapruk N, McErlane SA, Soja PJ. State-related inhibition by GABA and glycine of transmission in Clarke's column. J Neurosci 2002;22:5777-88.
56. Pace-Schott EF, Hobson JA. The neurobiology of sleep: genetics, cellular physiology and subcortical networks. Nat Rev Neurosci 2002;3:591-605.
57. Strecker RE, Nalwalk J, Dauphin LJ, Thakkar MM, Chen Y, Ramesh V et al. Extracellular histamine levels in the feline preoptic/anterior hypothalamic area during natural sleep-wakefulness and prolonged wakefulness: an in vivo microdialysis study. Neuroscience 2002;113:663-70.
58. Siegel JM. The neurobiology of sleep. Semin Neurol 2009;29:277-96.
59. Siegel JM, Tomaszewski KS, Wheeler RL. Behavioral organization of reticular formation: studies in the unrestrained cat. II. Cells related to facial movements. J Neurophysiol 1983;50:717-23.
60. Siegel JM, Nienhuis R, Fahringer HM, Paul R, Shiromani P, Dement WC et al. Neuronal activity in narcolepsy: identification of cataplexy-related cells in the medial medulla. Science 1991;252:1315-8.
61. Lin JS, Sakai K, Jouvet M. Evidence for histaminergic arousal mechanisms in the hypothalamus of cat. Neuropharmacology 1988;27:111-22.
62. Steininger TL, Alam MN, Gong H, Szymusiak R, McGinty D. Sleep-waking discharge of neurons in the posterior lateral hypothalamus of the albino rat. Brain Res 1999;840:138-47.
63. Vanni-Mercier G, Gigout S, Debilly G, Lin JS. Waking selective neurons in the posterior hypothalamus and their response to histamine H3-receptor ligands: an electrophysiological study in freely moving cats. Behav Brain Res 2003;144:227-41.
64. Watanabe T, Yanai K. Studies on functional roles of the histaminergic neuron system by using pharmacological agents, knockout mice and positron emission tomography. Tohoku J Exp Med 2001;195:197-217.
65. Fenik VB, Davies RO, Kubin L, Noradrenergic, serotonergic and GABAergic antagonists injected together into the XII nucleus abolish the REM sleep-like depression of hypoglossal motoneuronal activity. J Sleep Res 2005;14:419-29.
66. Jelev A, Sood S, Liu H, Nolan P, Horner RL. Microdialysis perfusion of 5-HT into hypoglossal motor nucleus differentially modulates genioglossus activity across natural sleep-wake states in rats. J Physiol 2001;532(Pt 2):467-81.
67. Sood S, Raddatz E, Liu X, Liu H, Horner RL. Inhibition of serotonergic medullary raphe obscurus neurons suppresses genioglossus and diaphragm activities in anesthetized but not conscious rats. J Appl Physiol 2006;100:1807-21.
68. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 2005;437:1257-63.
69. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998;92:573-85.
70. de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Nad Acad Sci U S A 1998;95:322-7.
71. Ebrahim IO, Howard RS, Kopelman MD, Sharief MK, Williams AJ. The hypocretin/orexin system. J R Soc Med 2002;95:227-30.
72. Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999;98:365-76.
73. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999;98:437-51.
74. Mignot E, Nishino S, Sharp LH, Arrigoni J, Siegel JM, Reid MS et al. Heterozygosity at the canarc-1 locus can confer susceptibility for narcolepsy: induction of cataplexy in heterozygous asymptomatic dogs after administration of a combination of drugs acting on monoaminergic and cholinergic systems. J Neurosci 1993;13:1057-64.
75. John J, Wu MF, Siegel JM. Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs. Sleep Res Online 2000;3:23-8.
76. Deadwyler SA, Porrino L, Siegel JM, Hampson RE. Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci 2007;27:14239-47.
77. Tokita S, Chemelli RM, Willie JT. Behavioral characterization of orexin-2 receptor (OX2R) knockout mice. Sleep 2001;24:A20-A21.
78. Kisanuki Y, Chemelli RM, Tokita S, Willie JT, Sinton CM, Yanagisawa M. Behavioral and Polysomnographic characterization of orexin-1 receptor and orexin-2 receptor double knockout mice. Sleep 2001;24:A22.
79. Peterson PC, Husain AM. Pediatric narcolepsy. Brain Dev 2008;30:609-23.
80. Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469-74.
81. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6:991-7.
82. Ripley B, Overeem S, Fujiki N, Nevsimalova S, Uchino M, Yesavage J et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 2001;57:2253-8.
83. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000;355:39-44.
84. Kanbayashi T, Yano T, Ishiguro H, Kawanishi K, Chiba S, Aizawa R et al. Hypocretin-1 (orexin-A) levels in human lumbar CSF in different age groups: infants to elderly persons. Sleep 2002;25:337-9.
85. Krahn LE, Pankratz VS, Oliver L, Boeve BF, Silber MH. Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status. Sleep 2002;25:733-6.
86. Nishino S, Ripley B, Overeem S, Nevsimalova S, Lammers GJ, Vankova J et al. Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 2001;50:381-8.
87. Mignot E, Lammers GJ, Ripley B, Okun M, Nevsimalova S, Overeem S et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002;59:1553-62.
88. Dalai MA, Schuld A, Haack M, Uhr M, Geisler P, Eisensehr I et al. Normal plasma levels of orexin A (hypocretin-1) in narcoleptic patients. Neurology 2001;56:1749-51.
89. Tsukamoto H, Ishikawa T, Fujii Y, Fukumizu M, Sugai K, Kanbayashi T. Undetectable levels of CSF hypocretin-1 (orexin-A) in two prepubertal boys with narcolepsy. Neuropediatrics 2002;33:51-2.
90. Kubota H, Kanbayashi T, Tanabe Y, Ito M, Takanashi J, Kohno Y et al. Decreased cerebrospinal fluid hypocretin-1 levels near the onset of narcolepsy in 2 prepubertal children. Sleep 2003;26:555-7.
91. Elias CF, Saper CB, Maratos-Flier E, Tritos NA, Lee C, Kelly J et al. Chemically defined projections linking the mediobasal hypothalamus and the lateral hypothalamic area. J Comp Neurol 1998;402:442-59.
92. Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998;18:9996-10015.
93. Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci U S A 1999;96:10911-6.
94. Silber MH, Rye DB. Solving the mysteries of narcolepsy: the hypocretin story. Neurology 2001;56:1616-8.
95. Siegel JM. Hypocretin (orexin): role in normal behavior and neuropathology. Annu Rev Psychol 2004;55:125-48.
96. Estabrooke IV, McCarthy MT, Ko E, Chou TC, Chemelli RM, Yanagisawa M et al. Fos expression in orexin neurons varies with behavioral state. J Neurosci 2001;21:1656-62.
97. Mileykovskiy BY, Kiyashchenko LI, Siegel JM. Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron 2005;46:787-98.
98. Lee MG, Hassani OK, Jones BE. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J Neurosci 2005;25:6716-20.
99. Yoshida Y, Fujiki N, Nakajima T, Ripley B, Matsumura H, Yoneda H et al. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur J Neurosci 2001;14:1075-81.
100. Yoshimichi G, Yoshimatsu H, Masaki T, Sakata T. Orexin-A regulates body temperature in coordination with arousal status. Exp Biol Med (Maywood) 2001;226:468-76.
101. Matsumura K, Tsuchihashi T, Abe I. Central orexin-A augments sympathoadrenal outflow in conscious rabbits. Hypertension 2001;37:1382-7.
102. Siegel JM, Boehmer LN. Narcolepsy and the hypocretin system - where motion meets emotion. Nat Clin Pract Neurol 2006;2:548-56.
103. Gulyani S, Wu MF, Nienhuis R, John J, Siegel JM. Cataplexy-related neurons in the amygdala of the narcoleptic dog. Neuroscience 2002;112:355-65.
104. Kiyashchenko LI, Mileykovskiy BY, Maidment N, Lam HA, Wu MF, John J et al. Release of hypocretin (orexin) during waking and sleep states. J Neurosci 2002;22:5282-6.
105. Erlich SS, Itabashi HH. Narcolepsy: a neuropathologic study. Sleep 1986;9(1 Pt 2):126-32.
106. Gerashchenko D, Murillo-Rodriguez E, Lin L, Xu M, Hallett L, Nishino S et al. Relationship between CSF hypocretin levels and hypocretin neuronal loss. Exp Neurol 2003;184:1010-6.
107. Thannickal TC, Lai YY, Siegel JM. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 2007;130(Pt 6):1586-95.
108. Fronczek R, Overeem S, Lee SY, Hegeman IM, van Pelt J, van Duinen SG et al. Hypocretin (orexin) loss and sleep disturbances in Parkinson's Disease. Brain 2008;131(Pt 1):e88.
109. Fronczek R, Overeem S, Lee SY, Hegeman IM, van Pelt J, van Duinen SG et al. Hypocretin (orexin) loss in Parkinson's disease. Brain 2007;130(Pt 6):1577-85.
110. Overeem S, Dalmau J, Bataller L, Nishino S, Mignot E, Verschuuren J et al. Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis. Neurology 2004;62 138-40.
111. Arii J, Kanbayashi T, Tanabe Y, Sawaishi Y, Kimura S, Watanabe A et al. CSF hypocretin-1 (orexin-A) levels in childhood narcolepsy and neurologic disorders. Neurology 2004;63:2440-2.
112. Kanbayashi T, Ishiguro H, Aizawa R, Saito Y, Ogawa Y, Abe M et al. Hypocretin-1 (orexin-A) concentrations in cerebrospinal fluid are low in patients with Guillain-Barre syndrome. Psychiatry Clin Neurosci 2002;56:273-4.
113. Rubin RL, Hajdukovich RM, Mitler MM. HLA-DR2 association with excessive somnolence in narcolepsy does not generalize to sleep apnea and is not accompanied by systemic autoimmune abnormalities. Clin Immunol Immunopathol 1988;49:149-58.
114. Plazzi G, Montagna P, Provini F, Bizzi A, Cohen M, Lugaresi E. Pontine lesions in idiopathic narcolepsy. Neurology 1996;46:1250-4.
115. Fredrikson S, Carlander B, Billiard M, Unk H. CSF immune variables in patients with narcolepsy. Acta Neurol Scand 1990;81:253-4.
116. Tanaka S, Honda Y, Inoue Y, Honda M. Detection of autoantibodies against hypocretin, hcrtr1, and hcrtr2 in narcolepsy: anti-Hcrt system antibody in narcolepsy. Sleep 2006;29:633-8.
117. Black JL 3rd, Silber MH, Krahn LE, Avula RK, Walker DL, Pankratz VS et al. Studies of humoral immunity to preprohypocretin in human leukocyte antigen DQB1*0602-positive narcoleptic subjects with cataplexy. Biol Psychiatry 2005;58:504-9.
118. Black JL 3rd, Silber MH, Krahn LE, Fredrickson PA, Pankratz VS, Avula R et al. Analysis of hypocretin (orexin) antibodies in patients with narcolepsy. Sleep 2005;28:427-31.
119. Overeem S, Black JL 3rd, Lammers GJ. Narcolepsy: immunological aspects. Sleep Med Rev 2008;12:95-107.
120. Boehmer LN, Wu MF, John J, Siegel JM. Treatment with immunosuppressive and anti-inflammatory agents delays onset of canine genetic narcolepsy and reduces symptom severity. Exp Neurol 2004;188:292-9.
121. Hecht M, Lin L, Kushida CA, Umetsu DT, Taheri S, Einen M et al. Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy. Sleep 2003;26:809-10.
122. Dauvilliers Y, Abril B, Mas E, Michel F, Tafti M. Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment. Neurology 2009;73:1333-4.
123. Dauvilliers Y, Carlander B, Rivier F, Touchon J, Tafti M. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 2004;56:905-8.
124. Lecendreux M, Maret S, Bassetti C, Mouren MC, Tafti M. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res 2003;12:347-8.
125. Plazzi G, Poli F, Franceschini C, Parmeggiani A, Pirazzoli P, Bernardi F et al. Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy. J Neurol 2008;255:1549-54.
126. Schatzberg SJ, Cutter-Schatzberg K, Nydam D, Barrett J, Penn R, Flanders J et al. The effect of hypocretin replacement therapy in a 3-year-old Weimaraner with narcolepsy. J Vet Intern Med 2004;18:586-8.
127. Stores G. Recognition and management of narcolepsy. Arch Dis Child 1999;81:519-24.
128. Wise MS, Lynch J. Narcolepsy in children. Semin Pediatr Neurol 2001;8:198-206.
129. 129- Okun ML, Lin L, Pelin Z, Hong S, Mignot E. Clinical aspects of narcolepsy-cataplexy across ethnic groups. Sleep 2002;25:27-35.
130. Benca RM. Narcolepsy and excessive daytime sleepiness: diagnostic considerations, epidemiology, and comorbidities. J Clin Psychiatry 2007;68(Suppl 13):5-8.
131. Wise MS. Narcolepsy and other disorders of excessive sleepiness. Med Clin North Am 2004;88:597-610.
132. Kothare SV, Kaleyias J. Narcolepsy and other hypersomnias in children. Curr Opin Pediatr 2008;20:666-75.
133. Stores G. The protean manifestations of childhood narcolepsy and their misinterpretation. Dev Med Child Neurol 2006;48:307-10.
134. Serra L, Montagna P, Mignot E, Lugaresi E, Plazzi G. Cataplexy features in childhood narcolepsy. Mov Disord 2008;23:858-65.
135. Overeem S, Mignot E, van Dijk JG, Lammers GJ. Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol 2001;8:78-105.
136. Thorpy MJ. Cataplexy associated with narcolepsy: epidemiology, pathophysiology and management. CNS Drugs 2006;20:43-50.
137. Dahl RE, Holttum J, Trubnick L. A clinical picture of child and adolescent narcolepsy. J Am Acad Child Adolesc Psychiatry 1994;33:834-41.
138. Krahn LE, Lymp JF, Moore WR, Slocumb N, Silber MH. Characterizing the emotions that trigger cataplexy. J Neuropsychiatry Clin Neurosci 2005;17:45-50.
139. Anic-Labat S, Guilleminault C, Kraemer HC, Meehan J, Arrigoni J, Mignot E. Validation of a cataplexy questionnaire in 983 sleep-disorders patients. Sleep 1999;22:77-87.
140. Hayes D Jr. Narcolepsy with cataplexy in early childhood. Clin Pediatr (Phila) 2006;45:361-3.
141. Stahl SM, Layzer RB, Aminoff MJ, Townsend JJ, Feldon S. Continuous cataplexy in a patient with a midbrain tumor: the limp man syndrome. Neurology 1980;30:1115-8.
142. Simon DK, Nishino S, Scammell TE. Mistaken diagnosis of psychogenic gait disorder in a man with status cataplecticus ("limp man syndrome"). Mov Disord 2004;19:838-40.
143. Kandt RS, Emerson RG, Singer HS, Valle DL, Moser HW. Cataplexy in variant forms of Niemann-Pick disease. Ann Neurol 1982;12:284-8.
144. Parkes JD. Genetic factors in human sleep disorders with special reference to Norrie disease, Prader-Willi syndrome and Moebius syndrome. J Sleep Res 1999;8(Suppl 1):14-22.
145. Martinez-Rodriguez JE, Lin L, Iranzo A, Genis D, Marti MJ, Santamaria J et al. Decreased hypocretin-1 (Orexin-A) levels in the cerebrospinal fluid of patients with myotonic dystrophy and excessive daytime sleepiness. Sleep 2003;26:287-90.
146. Sturzenegger C, Bassetti CL. The clinical spectrum of narcolepsy with cataplexy: a reappraisal. J Sleep Res 2004;13:395-406.
147. Dahmen N, Kasten M, Muller MJ, Mittag K. Frequency and dependence on body posture of hallucinations and sleep paralysis in a community sample. J Sleep Res 2002;11:179-80.
148. Plazzi G, Serra L, Ferri R. Nocturnal aspects of narcolepsy with cataplexy. Sleep Med Rev 2008;12:109-28.
149. Ohayon MM. Prevalence of hallucinations and their pathological associations in the general population. Psychiatry Res 2000;97:153-64.
150. Ohayon MM, Priest RG, Caulet M, Guilleminault C. Hypnagogic and hypnopompic hallucinations: pathological phenomena? Br J Psychiatry 1996;169:459-67.
151. Girard TA, Cheyne JA. Timing of spontaneous sleep-paralysis episodes. J Sleep Res 2006;15:222-9.
152. Goode GB. Sleep paralysis. Arch Neurol 1962;6:228-34.
153. Guilleminault C, Pelayo R. Narcolepsy in prepubertal children. Ann Neurol 1998;43:135-42.
154. Harsh J, Peszka J, Hartwig G, Mitler M. Night-time sleep and daytime sleepiness in narcolepsy. J Sleep Res 2000;9:309-16.
155. Vernet C, Arnulf I. Narcolepsy with long sleep time: a specific entity? Sleep 2009;32:1229-35.
156. Nobili L, Beelke M, Besset A, Billiard M, Ferrillo F. Nocturnal sleep features in narcolepsy: a model-based approach. Rev Neurol (Paris) 2001;157(11 Pt 2):S82-6.
157. Dauvilliers Y, Rompre S, Gagnon JF, Vendette M, Petit D, Montplaisir J. REM sleep characteristics in narcolepsy and REM sleep behavior disorder. Sleep 2007;30:844-9.
158. Bahammam A. Periodic leg movements in narcolepsy patients: impact on sleep architecture. Acta Neurol Scand 2007;115:351-5.
159. Ferri R, Zucconi M, Manconi M, Bruni O, Ferini-Strambi L, Vandi S et al. Different periodicity and time structure of leg movements during sleep in narcolepsy/cataplexy and restless legs syndrome. Sleep 2006;29:1587-94.
160. Schenck CH, Mahowald MW. Motor dyscontrol in narcolepsy: rapid-eye-movement (REM) sleep without atonia and REM sleep behavior disorder. Ann Neurol 1992;32:3-10.
161. Ferri R, Franceschini C, Zucconi M, Vandi S, Poli F, Bruni O et al. Searching for a marker of REM sleep behavior disorder: submentalis muscle EMG amplitude analysis during sleep in patients with narcolepsy/ cataplexy. Sleep 2008;31:1409-17.
162. Maski KP, Kothare SV. Searching for marker of REM sleep behavior disorder: submentalis muscle EMG amplitude analysis during sleep in patients with narcolepsy/cataplexy. Sleep 2009;32:137.
163. Nightingale S, Orgill JC, Ebrahim IO, de Lacy SF, Agrawal S, Williams AJ. The association between narcolepsy and REM behavior disorder (RBD). Sleep Med 2005;6:253-8.
164. Billiard M. REM sleep behavior disorder and narcolepsy. CNS Neurol Disord Drug Targets 2009;8:264-70.
165. Fortuyn HA, Swinkels S, Buitelaar J, Renier WO, Furer JW, Rijnders CA et al. High prevalence of eating disorders in narcolepsy with cataplexy: a case-control study. Sleep 2008;31:335-41.
166. Chabas D, Foulon C, Gonzalez J, Nasr M, Lyon-Caen O, Willer JC et al. Eating disorder and metabolism in narcoleptic patients. Sleep 2007;30:1267-73.
167. Bell I. Diet histories in narcolepsy. In: Guilleminault C, Dement W, Passouant P, editors. Narcolepsy. Proceedings of the First International Symposium on Narcolepsy, July 1975. Montpellier, France. New York, NY: Spectrum publications: 1976. p. 221-7.
168. Dahmen N, Becht J, Engel A, Thommes M, Tonn P. Prevalence of eating disorders and eating attacks in narcolepsy. Neuropsychiatr Dis Treat 2008;4:257-61.
169. Kotagal S, Krahn LE, Slocumb N. A putative link between childhood narcolepsy and obesity. Sleep Med 2004;5:147-50.
170. Baker TL, Guilleminault C, Nino-Murcia G, Dement WC. Comparative Polysomnographic study of narcolepsy and idiopathic central nervous system hypersomnia. Sleep 1986;9(1 Pt 2):232-42.
171. Vandeputte M, de Weerd A. Sleep disorders and depressive feelings: a global survey with the Beck depression scale. Sleep Med 2003;4:343-5.
172. Chakravorty SS, Rye DB. Narcolepsy in the older adult: epidemiology, diagnosis and management. Drugs Aging 2003;20:361-76.
173. Billiard M, Bassetti C, Dauvilliers Y, Dolenc-Groselj L, Lammers GJ, Mayer G et al. EFNS guidelines on management of narcolepsy. Eur J Neurol 2006;13:1035-48.
174. Dahmen N, Kasten M, Wieczorek S, Gencik M, Epplen JT, Ullrich B. Increased frequency of migraine in narcoleptic patients: a confirmatory study. Cephalalgia 2003;23:14-9.
175. Dahmen N, Querings K, Grun B, Bierbrauer J. Increased frequency of migraine in narcoleptic patients. Neurology 1999;52:1291-3.
176. Luc ME, Gupta A, Birnberg JM, Reddick D, Kohrman MH. Characterization of symptoms of sleep disorders in children with headache. Pediatr Neurol 2006;34:7-12.
177. Littner MR, Kushida C, Wise M, Davila DG, Morgenthaler T, Lee-Chiong T et al. Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Sleep 2005;28:113-21.
178. Martin SK, Eastman CI. Sleep logs of young adults with self-selected sleep times predict the dim light melatonin onset. Chronobiol Int 2002;19:695-707.
179. Bradshaw DA, Yanagi MA, Pak ES, Peery TS, Ruff GA. Nighdy sleep duration in the 2-week period preceding multiple sleep latency testing. J Clin Sleep Med 2007;3:613-9.
180. Hoddes E, Zarcone V, Smythe H, Phillips R, Dement WC. Quantification of sleepiness: a new approach. Psychophysiology 1973;10:431-6.
181. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-5.
182. Drake C, Nickel C, Burduvali E, Roth T, Jefferson C, Pietro B. The pediatric daytime sleepiness scale (PDSS): sleep habits and school outcomes in middle-school children. Sleep 2003;26:455-8.
183. Kothare SV, Kaleyias J. The clinical and laboratory assessment of the sleepy child. Semin Pediatr Neurol 2008;15:61-9.
184. Section on Pediatric Pulmonology, Subcommittee on Obstructive Sleep Apnea Syndrome. American Academy of Pediatrics. Clinical practice guideline: diagnosis and management of childhood obstructive sleep apnea syndrome. Pediatrics 2002;109:704-12.
185. Nevsimalova S, Prihodova I, Kemlink D, Lin L, Mignot E. REM behavior disorder (RBD) can be one of the first symptoms of childhood narcolepsy. Sleep Med 2007;8:784-6.
186. Carskadon MA, Dement WC, Mitler MM, Roth T, Westbrook PR, Keenan S. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep 1986;9:519-24.
187. Arand D, Bonnet M, Hurwitz T, Mitler M, Rosa R, Sangal RB. The clinical use of the MSLT and MWT. Sleep 2005;28:123-44.
188. Kotagal S, Hartse KM, Walsh JK. Characteristics of narcolepsy in preteenaged children. Pediatrics 1990;85:205-9.
189. Singh M, Drake CL, Roth T. The prevalence of multiple sleep-onset REM periods in a population-based sample. Sleep 2006;29:890-5.
190. Aldrich MS, Chervin RD, Malow BA. Value of the multiple sleep latency test (MSLT) for the diagnosis of narcolepsy. Sleep 1997;20:620-9.
191. Wise MS. Childhood narcolepsy. Neurology 1998;50(2 Suppl 1):S37-42.
192. Gozal D, Wang M, Pope DW Jr. Objective sleepiness measures in pediatric obstructive sleep apnea. Pediatrics 2001;108:693-7.
193. Palm L, Persson E, Elmqvist D, Blennow G. Sleep and wakefulness in normal preadolescent children. Sleep 1989;12:299-308.
194. Fallone G, Owens JA, Deane J. Sleepiness in children and adolescents: clinical implications. Sleep Med Rev 2002;6:287-306.
195. Mitler MM, Doghramji K, Shapiro C. The maintenance of wakefulness test: normative data by age. J Psychosom Res 2000;49:363-5.
196. Mignot E, Young T, Lin L, Finn L. Nocturnal sleep and daytime sleepiness in normal subjects with HLA-DQB1*0602. Sleep 1999;22:347-52.
197. Honda Y, Juji T, Matsuki K, Naohara T, Satake M, Inoko H et al. HLA-DR2 and Dw2 in narcolepsy and in other disorders of excessive somnolence without cataplexy. Sleep 1986;9(1 Pt 2):133-42.
198. Mignot E, Hayduk R, Black J, Grumet FC, Guilleminault C. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 1997;20:1012-20.
199. Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet 2007;369:499-511.
200. Gibson ES, Powles AC, Thabane L, O'Brien S, Molnar DS, Trajanovic N et al. "Sleepiness" is serious in adolescence: two surveys of 3235 Canadian students. BMC Public Health 2006;6:116.
201. Bassetti C, Aldrich MS. Idiopathic hypersomnia. A series of 42 patients. Brain 1997;120(Pt 8):1423-35.
202. Billiard M, Dauvilliers Y. Idiopathic hypersomnia. Sleep Med Rev 2001;5:349-58.
203. Sasai T, Inoue Y, Komada Y, Sugiura T, Matsushima E. Comparison of clinical characteristics among narcolepsy with and without cataplexy and idiopathic hypersomnia without long sleep time, focusing on HLA-DRBK *)1501/DQB1( *)0602 finding. Sleep Med 2009;10:961-6.
204. Bruck D, Parkes JD. A comparison of idiopathic hypersomnia and narcolepsy-cataplexy using self report measures and sleep diary data. J Neurol Neurosurg Psychiatry 1996;60:576-8.
205. Arnulf I, Lin L, Gadoth N, File J, Lecendreux M, Franco P et al. Kleine-Levin syndrome: a systematic study of 108 patients. Ann Neurol 2008;63:482-93.
206. Critchley M, Hoffman H. The syndrome of periodic somnolence and morbid hunger (Kleine-Levin syndrome). BMJ 1942;33:137-9.
207. Lamarche LJ, Driver HS, Wiebe S, Crawford L, JM DEK. Nocturnal sleep, daytime sleepiness, and napping among women with significant emotional/behavioral premenstrual symptoms. J Sleep Res 2007;16:262-8.
208. Manber R, Bootzin RR. Sleep and the menstrual cycle. Healdi Psychol 1997;16:209-14.
209. Regal AR, Amigo MC, Cebrian E. [Sleep and women]. Rev Neurol 2009;49:376-82.
210. Guilleminault C, Stoohs R, Clerk A, Cetel M, Maistros P. A cause of excessive daytime sleepiness. The upper airway resistance syndrome. Chest 1993;104:781-7.
211. Liu X, Buysse DJ, Gentzler AL, Kiss E, Mayer L, Kapornai K et al. Insomnia and hypersomnia associated with depressive phenomenology and comorbidity in childhood depression. Sleep 2007;30:83-90.
212. Lim CG, Ooi YP, Fung DS, Mahendran R, Kaur A. Sleep disturbances in Singaporean children with attention deficit hyperactivity disorder. Ann Acad Med Singapore 2008;37:655-61.
213. Krahn LE, Hansen MR, Shepard JW. Pseudocataplexy. Psychosomatics 2001;42:356-8.
214. Krahn LE. Reevaluating spells initially identified as cataplexy. Sleep Med 2005;6:537-42.
215. Black JE, Brooks SN, Nishino S. Narcolepsy and syndromes of primary excessive daytime somnolence. Semin Neurol 2004;24:271-82.
216. Nishino S, Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev 2005;9:269-310.
217. Guilleminault C, Yuen KM, Gulevich MG, Karadeniz D, Leger D, Philip P. Hypersomnia after head-neck trauma: a medicolegal dilemma. Neurology 2000;54:653-9.
218. Malik S, Boeve BF, Krahn LE, Silber MH. Narcolepsy associated with other central nervous system disorders. Neurology 2001;57:539-41.
219. Scammell TE, Nishino S, Mignot E, Saper CB. Narcolepsy and low CSF orexin (hypocretin) concentration after a thencephalic stroke. Neurology 2001;56:1751-3.
220. Clavelou P, Tournilhac M, Vidal C, Georget AM, Picard L, Merienne L. Narcolepsy associated with arteriovenous malformation of the diencephalon. Sleep 1995;18:202-5.
221. Schwartz WJ, Stakes JW, Hobson JA. Transient cataplexy after removal of a craniopharyngioma. Neurology 1984;34:1372-5.
222. Aldrich MS, Naylor MW. Narcolepsy associated with lesions of the diencephalon. Neurology 1989;39:1505-8.
223. Arii J, Kanbayashi T, Tanabe Y, Ono J, Nishino S, Kohno Y. A hypersomnolent girl with decreased CSF hypocretin level after removal of a hypothalamic tumor. Neurology 2001;56:1775-6.
224. Manni R, Politini L, Nobili L, Ferrillo F, Livieri C, Veneselli E et al. Hypersomnia in the Prader Willi syndrome: clinical-electrophysiological features and underlying factors. Clin Neurophysiol 2001;112:800-5.
225. Vossler DG, Wyler AR, Wilkus RJ, Gardner-Walker G, Vlcek BW. Cataplexy and monoamine oxidase deficiency in Norrie disease. Neurology 1996;46:1258-61.
226. Mitler MM, Carskadon MA, Czeisler CA, Dement WC, Dinges DF, Graeber RC. Catastrophes, sleep, and public policy: consensus report. Sleep 1988;11:100-9.
227. Findley LJ, Suratt PM, Dinges DF. Time-on-task decrements in "steer clear" performance of patients with sleep apnea and narcolepsy. Sleep 1999;22:804-9.
228. Broughton R, Ghanem Q, Hishikawa Y, Sugita Y, Nevsimalova S, Roui B. Life effects of narcolepsy in 180 patients from North America, Asia and Europe compared to matched controls. Can J Neurol Sci 1981;8:299-304.
229. McCartt AT, Rohrbaugh JW, Hammer MC, Fuller SZ. Factors associated with falling asleep at the wheel among long-distance truck drivers. Accid Anal Prev 2000;32:493-504.
230. Leechawengwongs M, Leechawengwongs E, Sukying C, Udomsubpayakul U. Role of drowsy driving in traffic accidents: a questionnaire survey of Thai commercial bus/truck drivers. J Med Assoc Thai 2006;89:1845-50.
231. Nabi H, Gueguen A, Chiron M, Lafont S, Zins M, Lagarde E. Awareness of driving while sleepy and road traffic accidents: prospective study in GAZEL cohort. BMJ 2006;333:75.
232. Rogers AE, Aldrich MS, Lin X. A comparison of three different sleep schedules for reducing daytime sleepiness in narcolepsy. Sleep 2001;24:385-91.
233. Mullington J, Broughton R. Scheduled naps in the management of daytime sleepiness in narcolepsy-cataplexy. Sleep 1993;16:444-56.
234. Wise MS, Arand DL, Auger RR, Brooks SN, Watson NF. Treatment of narcolepsy and other hypersomnias of central origin. An American Academy of Sleep Medicine Review. Sleep 2007;30:1712-27.
235. Husain AM, Yancy WS Jr, Carwile ST, Miller PP, Westman EC. Diet therapy for narcolepsy. Neurology 2004;62:2300-2.
236. Uttner M, Johnson SF, McCall WV, Anderson WM, Davila D, Hartse SK et al. Practice parameters for the treatment of narcolepsy: an update for 2000. Sleep 2001;24:451-66.
237. Yoss RE, Daly DD. On the treatment of narcolepsy. Med Clin North Am 1968;52:781-7.
238. Mitler MM, Aldrich MS, Koob GF, Zarcone VP. Narcolepsy and its treatment with stimulants. ASDA standards of practice. Sleep 1994;17:352-71.
239. Shindler J, Schachter M, Brincat S, Parkes JD. Amphetamine, mazindol, and fencamfamin in narcolepsy. Br Med J (Clin Res Ed) 1985;290:1167-70.
240. Mitler MM, Hajdukovic R, Erman M, Koziol JA. Narcolepsy. J Clin Neurophysiol 1990;7:93-118.
241. Mider MM, Hajdukovic R, Erman MK. Treatment of narcolepsy with methamphetamine. Sleep 1993;16:306-17.
242. Parkes JD, Dahlitz M. Amphetamine prescription. Sleep 1993;16:201-3.
243. Guilleminault C. Amphetamines and narcolepsy: use of the Stanford database. Sleep 1993;16:199-201.
244. Aldrich MS. Narcolepsy. N Engl J Med 1990;323:389-94.
245. Bassetti C, Aldrich MS. Narcolepsy. Neurol Clin 1996;14:545-71.
246. Mitler MM, Shafor R, Hajdukovich R, Timms RM, Browman CP. Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline. Sleep 1986;9(1 Pt 2):260-4.
247. Greenhill LL, Biederman J, Boellner SW, Rugino TA, Sangal RB, Earl CQ et al. A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45:503-11.
248. Rogers AE, Aldrich MS, Berrios AM, Rosenberg RS. Compliance with stimulant medications in patients with narcolepsy. Sleep 1997;20:28-33.
249. Honda Y, Hishikawa Y. A long-term treatment of narcolepsy and excessive daytime sleepiness with pemoline (Bentanamin). Current Therapeutic Research 1980;27:449-51.
250. Knoll J. Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand Suppl 1983;95:57-80.
251. Kuran W. [Selegiline (Jumex) in the treatment of narcolepsy]. Neurol Neurochir Pol 1993;27:131-3.
252. Mayer G, Ewert Meier K, Hephata K. Selegeline hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study. Clin Neuropharmacol 1995;18:306-19.
253. Reinish LW, MacFarlane JG, Sandor P, Shapiro CM. REM changes in narcolepsy with selegiline. Sleep 1995;18:362-7.
254. Hublin C, Partinen M, Heinonen EH, Puukka P, Salmi T. Selegiline in the treatment of narcolepsy. Neurology 1994;44:2095-101.
255. Schneider LS, Tariot PN, Goldstein B. Therapy with 1-deprenyl (selegiline) and relation to abuse liability. Clin Pharmacol Ther 1994;56(6 Pt 2):750-6.
256. Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert FA, Fuxe K. Modafinil: an antinarcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers. Biol Psychiatry 1997;42:1181-3.
257. Wyatt RJ, Fram DH, Buchbinder R, Snyder F. Treatment of intractable narcolepsy with a monoamine oxidase inhibitor. N Engl J Med 1971;285:987-91.
258. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol, 1998;43:88-97.
259. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000;54:1166-75.
260. Lin JS, Roussel B, Akaoka H, Fort P, Debilly G, Jouvet M. Role of catecholamines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the cat. Brain Res 1992;591:319-26.
261. Mignot E, Nishino S, Guilleminault C, Dement WC. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994;17:436-7.
262. Ferraro L, Tanganelli S, O'Connor WT, Antonelli T, Rambert F, Fuxe K. The vigilance promoting drug modafinil decreases GABA release in the medial preoptic area and in the posterior hypothalamus of the awake rat: possible involvement of the serotonergic 5-HT3 receptor. Neurosci Lett 1996;220:5-8.
263. Broughton RJ, Fleming JA, George CF, Hill JD, Kryger MH, Moldofsky H et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997;49:444-51.
264. Boivin DB, Montplaisir J, Petit D, Lambert C, Lubin S. Effects of modafinil on symptomatology of human narcolepsy. Clin Neuropharmacol 1993;16:46-53.
265. Billiard M, Besset A, Montplaisir J, Laffont F, Goldenberg F, Weill JS et al. Modafinil: a double-blind multicentric study. Sleep 1994;17(8 Suppl):S107-12.
266. Gold LH, Balster RL. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology (Berl) 1996;126:286-92.
267. Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol 2000;14:53-60.
268. Mitler MM, Harsh J, Hirshkowitz M, Guilleminault C. Long-term efficacy and safety of modafinil (PROVIGIL(R))) for the treatment of excessive daytime sleepiness associated with narcolepsy. Sleep Med 2000;1:231-43.
269. Biederman J, Swanson JM, Wigal SB, Boellner SW, Earl CQ, Lopez FA. A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study. J Clin Psychiatry 2006;67:727-35.
270. Biederman J, Swanson JM, Wigal SB, Kratochvil CJ, Boellner SW, Earl CQ et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics 2005;116:e777-84.
271. Swanson JM, Greenhill LL, Lopez FA, Sedillo A, Earl CQ, Jiang JG et al. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyper-activity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry 2006;67:137-47.
272. Dinges DF, Arora S, Darwish M, Niebler GE. Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss. Curr Med Res Opin 2006;22:159-67.
273. Harsh JR, Hayduk R, Rosenberg R, Wesnes KA, Walsh JK, Arora S et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 2006;22:761-74.
274. Roth T, White D, Schmidt-Nowara W, Wesnes KA, Niebler G, Arora S et al. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. Clin Ther 2006;28:689-706.
275. Laborit H. Sodium 4-Hydroxybutyrate. Int J Neuropharmacol 1964;3:433-51.
276. Laborit H. [Correlations between protein synthesis and serotonin in various activities of the central nervous system. (Slow and desynchronized sleep, learning and memory, sexual activity, morphine tolerance, aggressivity, Na gammahydroxybutyrate pharmacology]. Agressologie 1971;12:9-23.
277. Mamelak M, Escriu JM, Stokan O. Sleep-inducing effects of gammahydroxybutyrate. Lancet 1973;2:328-9.
278. Mamelak M, Webster P. Treatment of narcolepsy and sleep apnea with gammahydroxybutyrate: a clinical and Polysomnographic case study. Sleep 1981;4:105-11.
279. 279- Broughton R, Mamelak M. Effects of nocturnal gamma-hydroxybutyrate on sleep/waking patterns in narcolepsy-cataplexy. Can J Neurol Sci 1980;7:23-31.
280. Scrima L, Hartman PG, Johnson FH Jr, Thomas EE, Hiller FC. The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study. Sleep 1990;13:479-90.
281. Lammers GJ, Arends J, Declerck AC, Ferrari MD, Schouwink G, Troost J. Gammahydroxybutyrate and narcolepsy: a double-blind placebo-controlled study. Sleep 1993;16:216-20.
282. Tunnicliff G. Significance of gamma-hydroxybutyric acid in the brain. Gen Pharmacol 1992;23:1027-34.
283. Madden TE, Johnson SW. Gamma-hydroxybutyrate is a GABAB receptor agonist that increases a potassium conductance in rat ventral tegmental dopamine neurons. J Pharmacol Exp Ther 1998;287:261-5.
284. Brenneisen R, Elsohly MA, Murphy TP, Passarelli J, Russmann S, Salamone SJ et al. Pharmacokinetics and excretion of gamma-hydroxybutyrate (GHB) in healthy subjects. J Anal Toxicol 2004;28:625-30.
285. Borgen LA, Cook HN, Hornfeldt CS, Fuller DE. Sodium oxybate (GHB) for treatment of cataplexy. Pharmacotherapy 2002;22:798-9; discussion 799.
286. Borgen LA, Okerholm R, Morrison D, Lai A. The influence of gender and food on the pharmacokinetics of sodium oxybate oral solution in healthy subjects. J Clin Pharmacol 2003;43:59-65.
287. Borgen LA, Okerholm RA, Lai A, Scharf MB. The pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients. J Clin Pharmacol 2004;44:253-7.
288. Abanades S, Farre M, Segura M, Pichini S, Barrai D, Pacifici R et al. Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics. Ann N Y Acad Sci 2006;1074:559-76.
289. Goodwin AK, Brown PR, Jansen EE, Jakobs C, Gibson KM, Weerts EM. Behavioral effects and pharmacokinetics of gamma-hydroxybutyrate (GHB) precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) in baboons. Psychopharmacology (Berl) 2009;204:465-76.
290. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003;26:31-5.
291. U.S. Xyrem Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004;5:119-23.
292. Xyrem International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med 2005;1:391-7.
293. [No authors listed]. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002;25:42-9.
294. Murali H, Kotagal S. Off-label treatment of severe childhood narcolepsy-cataplexy with sodium oxybate. Sleep 2006;29:1025-9.
295. Tarabar AF, Nelson LS. The gamma-hydroxybutyrate withdrawal syndrome. Toxicol Rev 2004;23:45-9.
296. Hart CL, Haney M, Vosburg SK, Comer SD, Gunderson E, Foltin RW. Modafinil attenuates disruptions in cognitive performance during simulated night-shift work. Neuropsychopharmacology 2006;31:1526-36.
297. Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 2006;29:939-46.
298. Larrosa O, de la Uave Y, Bario S, Granizo JJ, Garcia-Borreguero D. Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study. Sleep 2001;24:282-5.
299. 299- Lammers GJ, Arends J, Declerck AC, Kamphuisen HA, Schouwink G, Troost J. Ritanserin, a 5-HT2 receptor blocker, as add-on treatment in narcolepsy. Sleep 1991;14:130-2.
300. Mayer G. Ritanserin improves sleep quality in narcolepsy. Pharmacopsychiatry 2003;36:150-5.
301. Guilleminault C, Aftab FA, Karadeniz D, Philip P, Leger D. Problems associated with switch to modafinil - a novel alerting agent in narcolepsy. Eur J Neurol 2000;7:381-4.
302. Frenette E, Kushida CA. Primary hypersomnias of central origin. Semin Neurol 2009;29:354-67.
303. Xyrem International Study Group.Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med 2005;6:415-21.
304. Thorpy M. Orally administered sodium oxybate for the treatment of narcolepsy. Curr Neurol Neurosci Rep 2004;4:155-6.
305. Thorpy MJ. Sodium oxybate for the treatment of narcolepsy. Expert Opin Pharmacother 2005;6:329-35.
306. Akimoto H, Honda Y, Takahashi Y. Pharmacotherapy in narcolepsy. Dis Nerv Syst 1960;21:704-6.
307. Dauvilliers Y, Billiard M, Montplaisir J. Clinical aspects and pathophysiology of narcolepsy. Clin Neurophysiol 2003;114:2000-17.
308. Poryazova R, Siccoli M, Werth E, Bassetti CL. Unusually prolonged rebound cataplexy after withdrawal of fluoxetine. Neurology 2005;65:967-8.
309. Schmidt HS, Clark RW, Hyman PR. Protriptyline: an effective agent in the treatment of the narcolepsy-cataplexy syndrome and hypersomnia. Am J Psychiatry 1977;134:183-5.
310. Schachter M, Parkes JD. Fluvoxamine and clomipramine in the treatment of cataplexy. J Neurol Neurosurg Psychiatry 1980;43:171-4.
311. Guilleminault C, Raynal D, Takahashi S, Carskadon M, Dement W. Evaluation of short-term and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride. Acta Neurol Scand 1976;54:71-87.
312. Shapiro WR. Treatment of Cataplexy with Clomipramine. Arch Neurol 1975;32:653-6.
313. Langdon N, Shindler J, Parkes JD, Bandak S. Fluoxetine in the treatment of cataplexy. Sleep 1986;9:371-3.
314. Frey J, Darbonne C. Fluoxetine suppresses human cataplexy: a pilot study. Neurology 1994;44:707-9.
315. Schrader H, Kayed K, Bendixen Markset AC, Treidene HE. The treatment of accessory symptoms in narcolepsy: a double-blind cross-over study of a selective serotonin re-uptake inhibitor (femoxetine) versus placebo. Acta Neurol Scand 1986;74:297-303.
316. Abad VC, Guilleminault C. Emerging drugs for narcolepsy. Expert Opin Emerg Drugs 2004;9:281-91.
317. Mignot E, Nishino S. Emerging therapies in narcolepsy-cataplexy. Sleep 2005;28:754-63.
318. Roselaar SE, Langdon N, Lock CB, Jenner P, Parkes JD. Selegiline in narcolepsy. Sleep 1987;10:491-5.
319. Iijima S, Sugita Y, Teshima Y, Hishikawa Y. Therapeutic effects of mazindol on narcolepsy. Sleep 1986;9(1 Pt 2):265-8.
320. Vespignani H, Barroche G, Escaillas JP, Weber M. Importance of mazindol in the treatment of narcolepsy. Sleep 1984;7:274-5.
321. Thorpy MJ, Snyder M, Aloe FS, Ledereich PS, Starz KE. Short-term triazolam use improves nocturnal sleep of narcoleptics. Sleep 1992;15:212-6.
322. Mieda M, Willie JT, Hara J, Sinton CM, Sakurai T, Yanagisawa M. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Nad Acad Sci U S A 2004;101:4649-54.
323. Arias-Carrion O, Murillo-Rodriguez E. Cell transplantation: a future therapy for narcolepsy? CNS Neurol Disord Drug Targets 2009;8:309-14.
324. Arias-Carrion O, Drucker-Colin R, Murillo-Rodriguez E. Survival rates through time of hypocretin grafted neurons within their projection site. Neurosci Lett 2006;404:93-7.
325. Arias-Carrion O, Murillo-Rodriguez E, Xu M, Bianco-Centurion C, Drucker-Colin R, Shiromani PJ. Transplantation of hypocretin neurons into the pontine reticular formation: preliminary results. Sleep 2004;27:1465-70.
326. Chen W, Black J, Call P, Mignot E. Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis. Ann Neurol 2005;58:489-90.
327. Barbier AJ, Berridge C, Dugovic C, Laposky AD, Wilson SJ, Boggs J et al. Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br J Pharmacol 2004;143:649-61.
328. Tedford CE, Phillips JG, Gregory R, Pawlowski GP, Fadnis L, Khan MA etal. Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands. J Pharmacol Exp Ther 1999; 289:1160-8.
329. Riehl J, Honda K, Kwan M, Hong J, Mignot E, Nishino S. Chronic oral administration of CG-3703, a thyrotropin releasing hormone analog, increases wake and decreases cataplexy in canine narcolepsy. Neuropsychopharmacology 2000;23:34-45.
330. Nishino S, Arrigoni J, Shelton J, Kanbayashi T, Dement WC, Mignot E. Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. J Neurosci 1997;17:6401-8.
331. 331- Broberger C, McCormick DA. Excitatory effects of thyrotropin-releasing hormone in the thalamus. J Neurosci 2005;25:1664-73.